Nasal Vaccines: A New Frontier in Flu Prevention Research
In the ongoing battle against influenza, a respiratory virus that affects millions worldwide each year, researchers are turning their attention to the body's first line of defense: the nasal mucosa. The Malaghan Institute of Medical Research in New Zealand has been at the forefront of this effort, exploring innovative nasal spray technologies that could provide robust protection right at the point of viral entry. This approach promises to revolutionize how we combat flu, potentially reducing transmission and severity by generating localized immune responses.
Influenza, commonly known as the flu, is caused by influenza viruses primarily of types A and B. These viruses evolve rapidly through antigenic drift and shift, making annual vaccines a necessity but often less than perfectly matched. Traditional intramuscular vaccines stimulate systemic immunity, producing circulating antibodies that may not effectively neutralize the virus in the upper respiratory tract where infection begins. Nasal vaccines, delivered directly to the mucosa, aim to elicit secretory immunoglobulin A (IgA) antibodies and tissue-resident immune cells for sterilizing immunity—preventing infection altogether.
New Zealand's unique research ecosystem, bolstered by institutes like Malaghan, positions the country as a hub for such advancements. With close ties to higher education institutions, this work not only advances science but also trains the next generation of immunologists.
Malaghan Institute's Breakthrough Insights on NKT Cells
Led by postdoctoral researcher Dr. Isabelle Montgomerie in the Connor Laboratory, a December 2025 study published in Mucosal Immunology unveiled the critical role of natural killer T (NKT) cells in nasal-associated lymphoid tissue (NALT). These unconventional T cells, distinct from conventional CD4 T helper cells which are scarce in the nasal cavity, assist B cells in forming germinal centers—specialized sites where high-affinity antibodies are produced.
The research demonstrated that NKT cells drive robust, localized antibody responses against respiratory pathogens, remaining responsive even after repeated antigen exposure. In mouse models, intranasal delivery of NKT cell agonists alongside viral antigens enhanced germinal center formation and antibody quality, outperforming systemic vaccination in mucosal protection.
This finding paves the way for next-generation nasal spray vaccines incorporating lipid antigens to activate NKT cells directly. Imagine a simple spray that equips your nose with elite immune sentinels, ready to neutralize influenza before it spreads deeper. The Malaghan team is actively developing RNA-based intranasal vaccines, leveraging messenger RNA (mRNA) technology proven effective in COVID-19 vaccines.
Targeting MAIT Cells for Mucosal Defense Against Flu
Complementing the NKT research, earlier work from Dr. Lisa Connor's team highlighted mucosal-associated invariant T (MAIT) cells as another key player. These innate-like T cells patrol mucosal barriers like the nose and lungs, poised to intercept threats such as influenza and SARS-CoV-2.
In preclinical studies, nasal administration of synthetic MAIT cell agonists with influenza virus components activated dendritic cells without causing inflammation, boosting secretory IgA production. This step-by-step process—agonist binding to MAIT cells, dendritic cell maturation, T follicular helper cell differentiation, and B cell activation—creates layered mucosal immunity superior to injections.
- Enhanced local antibody production at infection sites
- Reduced viral replication in upper airways
- Safer profile for vulnerable populations, avoiding systemic side effects
- Potential for broad protection across influenza subtypes
PhD candidate Kaitlin Buick, jointly supervised by Malaghan and Te Herenga Waka—Victoria University of Wellington, contributed key data, exemplifying the institute's higher education pipeline.
Expert Perspectives: Aligning with Global Breakthroughs
Dr. Montgomerie's commentary on a recent Harvard-led phase 1 trial of CR9114, a broad-spectrum anti-influenza antibody nasal spray, underscores synergies. Published in early 2026, the trial showed the spray safely neutralizing influenza A and B strains in humans and primates when dosed twice daily. While antibodies cleared quickly (within hours), it offers short-term prophylaxis ideal for outbreak surges.
"Nasal delivery achieves high local concentrations with minimal doses, complementing vaccines for high-risk groups like healthcare workers," Montgomerie noted. Malaghan's mRNA antibody platforms and Ferrier Research Institute collaborations aim to extend duration and affordability, bridging to clinical translation.
Photo by Tyler Lastovich on Unsplash
Victoria University Collaboration Fuels Innovation
Housed on Victoria University's Kelburn campus since 2004, Malaghan benefits from a renewed 2025 partnership enabling joint PhD programs, shared facilities, and summer scholarships. This symbiosis draws students from across New Zealand universities, fostering expertise in immunology and vaccinology.
For aspiring researchers, opportunities abound in mucosal immunology labs. Programs blend coursework with hands-on vaccine development, preparing graduates for roles in biotech and academia. Explore research jobs or postdoc positions to contribute to such transformative work.
Implications for New Zealand's Flu Landscape
New Zealand faces seasonal flu waves peaking in winter, straining healthcare with up to 1,400 deaths annually pre-COVID. Nasal vaccines could curb community spread, especially in Māori and Pasifika communities disproportionately affected.
Statistics from the Institute of Environmental Science and Research (ESR) show vaccination coverage at 40-50%, underscoring need for user-friendly options. Malaghan's culturally attuned research, including RNA platforms for rapid adaptation, positions NZ for pandemic preparedness.Read the full study summary.
Challenges and Pathways to Clinical Trials
Key hurdles include ensuring antigen stability in sprays, optimizing dosing, and scaling manufacturing. Malaghan addresses these via Horizon Europe funding and local partnerships.
- Preclinical optimization in animal models
- Phase 1 safety in humans
- Efficacy challenge trials
- Large-scale field studies
Timeline: Intranasal candidates could enter trials by 2027-2028, accelerating if aligned with global efforts like CEPI's universal flu vaccine push.
Future Outlook: Toward Universal Flu Protection
Combining NKT/MAIT targeting with broad antibodies, nasal sprays may evolve into pan-influenza shields. For NZ higher education, this heralds growth in biotech jobs, with Victoria and Otago universities poised to lead.
Stakeholders—from policymakers to patients—anticipate reduced hospitalizations and economic burden. Actionable insight: Support research funding and pursue university jobs in immunology.
Explore MAIT cell research.
Career Opportunities in NZ Vaccine Research
This field offers rewarding paths for graduates. Roles span lab technicians to principal investigators, with salaries averaging NZ$80,000-$150,000. Platforms like higher-ed-jobs list openings at Malaghan and partners.
- PhD scholarships in mucosal immunology
- Postdoctoral fellowships on RNA vaccines
- Industry transitions to biotech firms
Check academic CV tips to advance your career.
Conclusion: A Healthier Future Through Innovation
Malaghan Institute's nasal vaccine research exemplifies New Zealand's research prowess, promising flu protection via smart mucosal immunity. As trials progress, expect global impact. Aspiring academics, rate professors at Rate My Professor, browse higher ed jobs, or seek career advice. Stay informed and engaged in this vital field.